Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer's and Parkinson's Diseases
Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer's and Parkinson's Diseases
复制标题
DOI：
10.1007/s40263-018-0593-6
复制
发表时间：
2019-03-01
期刊：
影响因子：
6
通讯作者：
Ferreira, Sergio T.
中科院分区：
文献类型：
--
作者：
Batista, Andre F.;Bodart-Santos, Victor;Ferreira, Sergio T.
目前阿尔茨海默病（AD）和帕金森病（PD）的有效治疗方法的缺乏反映了对潜在疾病过程的不完整认识。研究这些疾病的中心病理特征已经付出了相当大的努力，从而产生了许多开发干扰这些特征的化合物的尝试。然而，在相互关联的AD和PD通路中的分子靶点的进一步表征仍然需要。脑胰岛素信号受损已成为阿尔茨海默病和帕金森病中导致神经元功能障碍的一个特征，导致旨在恢复大脑中这一途径的策略。用于治疗2型糖尿病的长效胰高血糖素样肽-1 （GLP-1）类似物已经在AD和PD的实验模型以及初步临床试验中进行了测试，并显示出令人鼓舞的保护作用。我们回顾了揭示GLP-1类似物在AD和PD临床前模型中的神经保护作用的研究以及最近临床试验的有希望的结果。
The current absence of effective treatments for Alzheimer's disease (AD) and Parkinson's disease (PD) reflects an incomplete knowledge of the underlying disease processes. Considerable efforts have been made to investigate the central pathological features of these diseases, giving rise to numerous attempts to develop compounds that interfere with such features. However, further characterization of the molecular targets within the interconnected AD and PD pathways is still required. Impaired brain insulin signaling has emerged as a feature that contributes to neuronal dysfunction in both AD and PD, leading to strategies aiming at restoring this pathway in the brain. Long-acting glucagon-like peptide-1 (GLP-1) analogues marketed for treatment of type 2 diabetes mellitus have been tested and have shown encouraging protective actions in experimental models of AD and PD as well as in initial clinical trials. We review studies revealing the neuroprotective actions of GLP-1 analogues in pre-clinical models of AD and PD and promising results from recent clinical trials.